Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
Research
X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome
BOSTON, Oct. 04, 2021 - X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) announced today that it has completed enrollment in the ongoing pivotal Phase 3 clinic…
Patient Education Webcasts
Living With Chronic Myeloid Leukemia (CML)
Eastern PA - Delaware Region Board of Trustees
The Eastern Pennsylvania - Delaware Region Board of Trustees is a group of distinguished individuals who serve as ambassadors for The Leukemia and Lym…
News
New Study Shows Most Blood Cancer Patients Benefit from an Additional COVID-19 Vaccine Dose
More than one in two patients with B-cell blood cancers produced antibodies to a third dose of COVID-19 vaccine despite having no detectable antibodie…
BACK-TO-SCHOOL SAFETY
As the new school year began across the country and shifted back to more in-person learning, LLS heard from families affected by blood cancer. Whether…
Georgia Blood Cancer Conference 2021
Free Educational Conference for Patients, Survivors, Caregivers and Healthcare Professionals*
Research
MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals
Planegg/Munich, Germany, July 15, 2021 - MorphoSys announced the successful completion of its previously announced cash tender offer for all outstandi…
Research
Ryvu Therapeutics
Krakow, Poland - Ryvu Therapeutics is a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address …
Research
Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform
Waltham, Mass., August 18, 2021 – Immunitas Therapeutics (“Immunitas”), a single cell genomics-based therapeutics company, today announced the complet…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
